BAX and cancer: While, DTX has shown to regulate BAX/BCL-2 ratio instead only suppressing the BCL-2 expression in a dose and time-dependent manner, miR-34a is well reported to downregulate the BCL-2 translation in cancer as well as neurodegenerative diseases12,50–52.